Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SANUWAVE Health, Inc.

http://www.sanuwave.com/

Latest From SANUWAVE Health, Inc.

Roche Inks Another AAV Capsid Platform Technology Deal, With Avista Therapeutics

Deal Snapshot: Roche and University of Pittsburgh spinout Avista Therapeutics signed the pact to enable the Swiss drug maker to develop gene therapies for retinal diseases using Avista’s platform tech.

Deals Gene Therapy

Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks

Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.

Deal Watch Business Strategies

Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology

Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.

Gene Therapy Deals

Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids

Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.

Financing Gene Therapy
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • SANUWAVE Inc
UsernamePublicRestriction

Register